BROOKE STEPHENS: Open Payments
NPI 1407245731 · MARRERO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,917 in 158 payments from 19 companies in 2025. Trend: 2023 $1,977 · 2024 $1,734 · 2025 $2,917
Food & beverage: $2,838Education: $79
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 71 | $1,056 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $242 |
| Janssen Biotech, Inc. | 9 | $229 |
| GENZYME CORPORATION | 8 | $192 |
| Gilead Sciences, Inc. | 10 | $191 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| PFIZER INC. | 6 | $123 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $99 |
| Celltrion USA Inc. | 5 | $95 |
| Ipsen Biopharmaceuticals, Inc | 4 | $89 |
Products named: RINVOQ, TREMFYA, DUPIXENT, SKYRIZI, ENTYVIO, VEGZELMA, IQIRVO, CREON.
Industry payments across LA — which companies pay providers there.
